REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Designated Organic Active Ingredient Containing (doai) > O-glycoside > > Nitrogen Containing Hetero Ring > 2,4-diketone Pyrimidine Or Derivative (e.g., Uracil, Etc.) 2,4-diketone Pyrimidine Or Derivative (e.g., Uracil, Etc.)2,4-diketone Pyrimidine Or Derivative (e.g., Uracil, Etc.) patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.11/16/06 - 20060258615 - Di(uridine 5'-)tetraphosphate and salts thereof The present invention are directed to P1,P4-di(uridine 5′-)tetraphosphate, tetra-alkali metal salts such as tetrasodium, tetralithium, tetrapotassium, and mixed tetra-alkali metal cations thereof. The tetra alkali metal salts of P1,P4-di(uridine 5′-)tetraphosphate are water-soluble, nontoxic, and easy to handle during manufacture. These tetra-monovalent alkali metal salts are more resistant to hydrolysis than ... 09/21/06 - 20060211649 - Use of cytisine for enhancing physical performance A method of decreasing fat and adipose tissue, and increasing endurance and alertness in humans comprises administering cytisine in a daily dosage between about 0.1 and 8 mg. Cytisine may be administered once per day or in multiple doses, either alone or in combination with other compounds and mixtures. ... 09/21/06 - 20060211648 - Naphthalimide compositions and uses thereof A method of treatment of a host with a cellular proliferative disease, comprising contacting the host with a naphthalimide and an antiproliferative agent, each in an amount sufficient to modulate said cellular proliferative disease, is described. In some embodiments, the naphthalimide comprises amonafide (5-amino-2-[2-(dimethylamine)ethyl]-1H-benz[de-]isoquinoline-1,3-(2H)-dione). Antiproliferative agents of the invention comprise ... 08/24/06 - 20060189566 - Muscle building agent and preventive or remedy for muscle weakening In accordance with the present invention, there can be provided a muscle building agent, a preventive or therapeutic agent for muscle wasting, food and drink or feed for muscle building or for prevention or treatment of muscle wasting, and a food and drink additive or a feed additive for muscle ... 03/30/06 - 20060069061 - Compositions containing uridine and choline, and methods utilizing same The present invention is directed to methods of improving cognitive and neurological functions and increasing synthesis and release of neurotransmitters and membrane synthesis by neural cells and brain cells, comprising administering a composition comprising a uridine and a choline. ... 03/09/06 - 20060052334 - Sequential therapy comprising a 20(s)-camptothecian and a pyrimidine base analog A method is provided for treating a patient having a disease associated with undesirable or uncontrolled cell proliferation, the method comprising: administering to the patient a 20(S)-camptothecin for a period of time during which a pyrimidine base analog is not being administered to the patient; and administering a pyrimidine base ... 02/02/06 - 20060025375 - Beta-l-2'-deoxy-nucleosides for the treatment of hepatitis b wherein R is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative; and BASE is a purine or pyrimidine base which may be optionally substituted. The ... 10/06/05 - 20050222078 - Use of pyrimidine nucleotides for the treatment of affections of the peripheral nervous system The invention relates to the use of a pyrimidine nucleotide for treating affections of the peripheral nervous system, particularly polyneuropathies, neuritides, and myopathies, and the use thereof for stimulating the regeneration of nerves. ... 08/04/05 - 20050171051 - Pharmaceutical composition for diabetic neuropathy The present invention relates to an agent for the prophylaxis or treatment of diabetic neuropathy, which contains cytidine 5′-diphosphocholine (CDP-choline) as an active ingredient. The agent for the prophylaxis or treatment of diabetic neuropathy of the present invention is effective for neuropathy mainly caused by metabolic disturbance of carbohydrate and ... 07/07/05 - 20050148540 - Di(uridine 5'-)tetraphosphate and salts thereof The present invention are directed to P1,P4-di(uridine 5′-)tetraphosphate, tetra-alkali metal salts such as tetrasodium, tetralithium, tetrapotassium, and mixed tetra-alkali metal cations thereof. The tetra alkali metal salts of P1,P4-di(uridine 5′-)tetraphosphate are water-soluble, nontoxic, and easy to handle during manufacture. These tetra-monovalent alkali metal salts are more resistant to hydrolysis than ... 07/07/05 - 20050148539 - Fused pentacyclic polyethers wherein R, OR1, and R2 are as defined herein. Also disclosed are methods of regulating mucus clearance in a cell, and methods of treating decreased mucus clearance or mucociliary dysfunction. ... 06/30/05 - 20050143339 - Aryl phosphate derivatives of d4t with potent anti-viral activity Methods for increasing the elimination half-life of key metabolites such as d4T by administering an aryl phosphate derivative of d4T having an electron withdrawing substituent on the aryl group and an amino acid substituent on the phosphate group are described. A preferred aryl phosphate derivative of d4T is HI-113 (d4T-5′-[p-bromophenyl ... 06/30/05 - 20050143338 - 1-(2,5'-anhydro-lyxofuranosyl) thymines for the synthesis of radiomarked fluoro-3 deoxynucleotides R′ represents hydrogen, a halogen, such as F, Cl, and Br, a substituted or unsubstituted C1-C7-alkyl group, such as methyl and ethyl, a substituted or unsubstituted C2-C7-alkenyl group, or a substituted or unsubstituted C2-C7-alkynyl group. ... 06/16/05 - 20050130931 - Compositions for the treatment of glaucoma or ocular hypertension The present invention is directed to a method of reducing intraocular pressure. The method comprises administering to a subject a pharmaceutical composition comprising an effective amount of a nucleoside 5′-pyrophosphate pyranoside or analogue, which is defined by general Formula I. The method of the present invention is useful in the ... ### FreshPatents.com Support |